Cancer Registry Software Market Size - By Product Type (Standalone, Integrated), Delivery Mode (On-premise, Cloud-based), Database (Commercial, Public), Functionality (Cancer Reporting, Patient Care Management), End-user, Global Forecast (2023 - 2032)

Cancer Registry Software Market Size

Cancer Registry Software Market size accounted for USD 71.4 million in 2022 and is estimated to grow at a CAGR of 10.5% to reach USD 193.4 million by 2032 attributed to the factors including rising cancer prevalence, increasing government initiatives for cancer treatment, growing adoption of EHR, and increasing emphasis on evidence-based medicine.
 

The information gathered with the aid of cancer registry software aids in the development of therapeutics for the treatment of cancer by researchers and medical professionals and helps in preventing the global spread of diseases. The government can track the patients in a specific area and location with the aid of this software.
 

In August 2021, the researchers from the International Agency for Research on Cancer IARC, the Northern Ireland Cancer Registry, and the Union for International Cancer Control (UICC) launched new software to facilitate cancer staging. Additionally, in October 2020, MOVEMBER launched the largest network of prostate cancer patient registries in world. By leveraging the 'real world' experiences of more than 130,000 men, this network will have the power to revolutionise the treatment and care of the disease. This initiative provides a more efficient and affordable digital solution, which enhances the infrastructure and lowers costs.
 

COVID-19 Impact Analysis

The COVID-19 pandemic caused a significant drop in cancer diagnostics during the pandemic, as well as a drop in cancer chemo, surgery, and other supportive therapies. During the pandemic, the number of cancer screenings decreased, which resulted in fewer cancer cases reported to cancer registries. This caused difficulties for cancer registries to track the prevalence and incidence of cancer. The disruption of healthcare services and workflow during the pandemic impacted the data accuracy and completeness in cancer registry software. The pandemic brought into focus the significance of seamless data integration and interoperability amongst healthcare systems. The importance of cancer registry software that can be integrated with electronic health records (EHRs), laboratory systems, and other healthcare information systems has grown.
 

Cancer Registry Software Market Driving Factors

The cancer registry software aids in tracking and keeping tabs on the health of cancer patients. Globally, 19.3 million new cases of cancer were reported in 2020, and according to data from the Global Cancer Observatory (GLOBOCAN), this number is expected to rise to 30.2 million by 2040. Additionally, according to projections from the International Agency for Research on Cancer (IARC) updates from July 2021, by 2040, the expected number of cancer-related deaths will reach to 16.3 million. The need for cancer registry software will increase because of these heavy burdens because it will be much easier to spot trends in the incidence and course of cancer.
 

Cancer Registry Software Market Analysis

Based on product type, the cancer registry software market is segmented into standalone software and integrated software. The standalone software segment will grow at 10% CAGR to reach USD 143.7 million by 2032.The standalone software is cost-effective, flexible, provides easy integration and data security. The use of standalone software is increasing in the healthcare industry mainly due to the industry’s changing landscape, the need to streamline and optimize workflows and decrease physician workloads.
 

Based on delivery mode, the cancer registry software market is segmented into on-premise and cloud-based. The on-premise segment is expected to grow at CAGR of 10.1% by 2032. The on-premise cancer registry software is mostly adopted by research institutes who are doing research on cancer as they deal with sensitive and confidential data for conducting research and the on-premise cancer registry software implement robust data security measures. The on-premise cancer registry software is embedded with advanced features which help to store data easily. The on-premise cancer registry software is less risky in terms of data security as compared to other types of models. The on-premise cancer registry software allows the organization to organization to implement their own security protocols and measures.
 

The cloud-based cancer registry software can be integrated with the real time data and standard guidelines. This software helps in the reduction of information technology overhead costs. In addition, the cloud-based cancer registry software is efficient in nature.
 

Based on database, the cancer registry software market is segmented into commercial database and public database. The commercial database segment accounted for highest market share of 72.5% in 2022. The data stored in the commercial database is quite safe as compared to public database and it can be easily tracked and used across research centres and government agencies.
 

The public database is used for the various cancer research programs. The utilization of public database is growing due to the increasing number of research centres all over the globe. The public database can help to track patient data from any corner of the world.
 

Based on functionality, the cancer registry software market is segmented into cancer reporting, patient care management, medical research and clinical studies, and product outcome evaluation. In 2022, the cancer reporting segment was valued to be USD 30. million. This functionality allows cancer registries to collect and manage the data on cancer cases to state and federal agencies. The incidence and deaths caused by cancer in a population is monitored using these data. It facilitates the cancer registries and healthcare organizations for collecting, analyzing, and reporting precise and standardized data, resulting in improved cancer care, advancements in research, and public health decision-making.
 

Based on end-user, the cancer registry software market is segmented into government organizations & third-party administration, research institutes, hospital & medical practices, private players, and pharmaceutical, biotech, & medical device companies. The government organizations and third-party administration segment is expected to grow at a CAGR of 10% by 2032. This software helps to track and monitor cancer patients in their respective region. In addition, the increased investments, and initiatives by government for the implementation of cancer registry software in hospitals.
 

The North America cancer registry software marketaccounted for market share of 51.6% in 2022. The industry in this region is growing due to the rising prevalence of cancer, well-developed healthcare infrastructure, increasing investments by government, and the growing demand for cancer registry software.
 

On the other hand, Asia-Pacific is anticipated to experience the fastest expansion by 2032. The governments of developing countries like China and Japan are constantly working to develop the market for cancer registry software.
 

Cancer Registry Software Market Share

Major market players operating in the cancer registry software market include :

• Elekta
• C/NET Solutions
• Electronic Registry Systems Inc.
• Onco Inc.
• McKesson Corporation
• Siemens Healthineers
• IBM Corporation
• Ordinal data, Inc.
•  Conduent, Inc.
• NeuralFrame, Inc

Cancer Registry Software Industry News:

• In May 2023, Elekta announced the launch of Elekta ONE, an advanced software for oncology departments and clinics. This development strengthened company’s product portfolio and is expected to boost revenue.
   
• In April 2018, Elekta and PalabraApps LLC formed a partnership to create the software that runs its MOSAIQ Oncology Information System. This development helped the company to enhance their product portfolio and customer base.
   

The cancer registry software market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Product Type

• Standalone software
• Integrated software

By Delivery Mode

• On-premise
• Cloud-based

By Database

• Commercial database
• Public database

By Functionality

• Cancer reporting
• Patient care management
• Medical research and clinical studies
• Product outcome evaluation 

By End-User

• Government organizations and third-party administration
• Research institutes
• Hospital & medical practices
• Private payers
• Pharmaceutical, biotech, and medical device companies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa